ImmuCell (NasdaqCM:ICCC) 2025 Conference September 30, 2025 04:15 PM ET Speaker0Hello, everyone, and thank you for joining us at the 2025 Lithium Partners Fall Investor Conference. My name is Joe Diaz. I'm a Managing Partner at Lithium Partners. Today, I'll be moderating a Q&A discussion with Michael Brigham, CEO, and Tim Fiori, CFO of ImmuCell Corporation, which trades on the NASDAQ under the ticker ICCC. Let's get started. Michael, Tim, thanks for joining us today. Michael, for the benefit of those in the ...

Elanco Animal Health Incorporated (ELAN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently an Operatin ...

LEXINGTON, Ky.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG) announced today that it has renewed its commitment to the United States Equestrian Federation, extending the relationship first launched last year. Since joining US Equestrian in April 2024, Neogen has provided valuable support, resources, and educational tools to benefit the Federation and its members. As part of the renewed collaboration, Neogen and US Equestrian will once again develop member-accessible educational materials. ...

Key Takeaways PAHC shares surge, driven by Animal Health, Zoetis portfolio and strong overseas demand.Phibro expands vaccine capacity; Q4 sales rise 21% YoY on poultry growth and strong international demand.Phibro's global reach spans high-growth livestock markets across South America, Asia, Europe and Africa.Phibro Animal Health (PAHC) shares have surged 82.1% so far this year, showcasing impressive momentum. This has outpaced the industry’s 5.3% growth and the S&P 500 Composite’s 14.2% gain.Carrying a Zac ...

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of a $250,000 grant. Canalevi ...

CHICAGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America, is proud to announce its participation in the upcoming World Dairy Expo in Madison, Wisconsin, where it will once again serve as the official Media Room sponsor. This marks the fourth consecutive year Amlan has supported the world’s largest dairy-focused event, underscoring the company’s commitment to advancing ruminant health and supporting global producers. “The era of single-to ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief. ...

核心财务表现 - 2025年上半年收入达7.383亿欧元 较2024年同期的7.029亿欧元增长5% [1][7] - 按固定汇率和范围计算有机增长达5.6% 其中销量增长贡献约2.1个百分点 价格增长贡献约3.5个百分点 [7] - 经常性经营利润(收购资产摊销前)为1.35亿欧元 同比下降10.2% 利润率从21.4%降至18.3% [1][9] - 集团净利润为8220万欧元 同比下降13.3% 集团份额净利润为8240万欧元 同比下降12.9% [1][10][12] 区域业绩分析 - 欧洲地区按固定汇率计算增长7.1% 其中西欧增长9.4% 中欧和东欧增长27.4% [8] - 北美地区按固定汇率和范围计算增长5.9% 但受分销商库存影响约5个百分点 [8] - 拉丁美洲增长8.2% 主要受墨西哥、哥伦比亚和巴西驱动 但智利水产业务下降11.2% [8] - IMEA地区增长8.2% 印度增长6.8% [8] - 远东亚洲增长2.8% 但越南因猪瘟疫情下降17.8% [8] - 太平洋地区下降7.9% 主要因澳大利亚下降11.4% [8] 现金流与资产负债 - 净债务为2.014亿欧元 较2024年底增加3290万欧元 主要受营运资金季节性影响和1210万欧元股息支付影响 [1][12] - 税前经营现金流为1.64亿欧元 同比下降5% [1] - 股东权益(集团份额)为10.651亿欧元 同比增长7.1% [1] 重大事项与战略 - 2024年4月收购日本Sasaeah公司贡献2.2个百分点增长 Mopsan收购贡献0.6个百分点增长 [7] - 研发费用持续增长 按固定汇率计算占收入比例增加0.4个百分点 [9] - 汇兑损失570万欧元 主要因欧元对智利比索(430万欧元)和墨西哥比索(140万欧元)升值 [11] - Paul Martingell于2025年9月1日就任首席执行官 [15] 2025年展望 - 确认全年收入增长目标为4%-6%(按固定汇率和范围计算) [13] - 预计经常性经营利润(收购资产摊销前)率将维持在16%左右 [13] - 现金状况预计改善8000万欧元(不含潜在收购) [13] - 美国关税潜在影响约400万美元 因当地生产占比达三分之二且2026年底将提升至近80% [14]

Zoetis Inc. (NYSE:ZTS) has shown resilience with a slight increase of 0.013% over the past month, despite a recent dip of 3.23% in the last 10 days.The company boasts a projected stock price increase of 21.28%, highlighting its significant growth potential and strong market position.Zoetis's financial health is solid, with a Piotroski Score of 8, indicating strong financial stability and operational efficiency.Zoetis Inc. (NYSE:ZTS) is a leading global animal health company, dedicated to the discovery, deve ...